Novartis Is Buying the Next Generation of PI3Kα — Before the Current Generation Has Finished Paying Off
Novartis's acquisition of SNV4818 from Synnovation Therapeutics isn't a gap-fill — it's a calculated preemption. In a breast cancer...
PI3Kα Inhibition